Thus, MYC mutational status and expression profile may also be a cofactor underlying the sensitivity of our model of p190+ ALL to PARP inhibition and future investigations are needed to fully elucidate this hypothesis. The gene discussed is PARP1; the disease is acute lymphoblastic leukemia.